Medication Cost Concerns and Disparities in Patient-Reported Outcomes Among a Multiethnic Cohort of Patients With Systemic Lupus Erythematosus
Copyright © 2023 by the Journal of Rheumatology..
OBJECTIVE: Concerns about the affordability of medications are common in systemic lupus erythematosus (SLE), but the relationship between medication cost concerns and health outcomes is poorly understood. We assessed the association of self-reported medication cost concerns and patient-reported outcomes (PROs) in a multiethnic SLE cohort.
METHODS: The California Lupus Epidemiology Study is a cohort of individuals with physician-confirmed SLE. Medication cost concerns were defined as having difficulties affording SLE medications, skipping doses, delaying refills, requesting lower-cost alternatives, purchasing medications outside the United States, or applying for patient assistance programs. Linear regression and mixed effects models assessed the cross-sectional and longitudinal association of medication cost concerns and PROs, respectively, adjusting for age, sex, race and ethnicity, income, principal insurance, immunomodulatory medications, and organ damage.
RESULTS: Of 334 participants, medication cost concerns were reported by 91 (27%). Medication cost concerns were associated with worse Systemic Lupus Activity Questionnaire (SLAQ; beta coefficient [β] 5.9, 95% CI 4.3-7.6; P < 0.001), 8-item Patient Health Questionnaire depression scale (PHQ-8; β 2.7, 95% CI 1.4-4.0; P < 0.001), and Patient-Reported Outcomes Measurement Information System (PROMIS; β for physical function -4.6, 95% CI -6.7 to -2.4; P < 0.001) scores after adjusting for covariates. Medication cost concerns were not associated with significant changes in PROs over 2-year follow-up.
CONCLUSION: More than a quarter of participants reported at least 1 medication cost concern, which was associated with worse PROs. Our results reveal a potentially modifiable risk factor for poor outcomes rooted in the unaffordability of SLE care.
| Errataetall: |
CommentIn: J Rheumatol. 2023 Oct;50(10):1205-1207. - PMID 37657797 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
The Journal of rheumatology - 50(2023), 10 vom: 16. Okt., Seite 1302-1309 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aguirre, Alfredo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug costs |
|---|
| Anmerkungen: |
Date Completed 05.10.2023 Date Revised 20.03.2024 published: Print-Electronic CommentIn: J Rheumatol. 2023 Oct;50(10):1205-1207. - PMID 37657797 Citation Status MEDLINE |
|---|
| doi: |
10.3899/jrheum.2023-0060 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358232309 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358232309 | ||
| 003 | DE-627 | ||
| 005 | 20240320233210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3899/jrheum.2023-0060 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM358232309 | ||
| 035 | |a (NLM)37321640 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aguirre, Alfredo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Medication Cost Concerns and Disparities in Patient-Reported Outcomes Among a Multiethnic Cohort of Patients With Systemic Lupus Erythematosus |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Rheumatol. 2023 Oct;50(10):1205-1207. - PMID 37657797 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by the Journal of Rheumatology. | ||
| 520 | |a OBJECTIVE: Concerns about the affordability of medications are common in systemic lupus erythematosus (SLE), but the relationship between medication cost concerns and health outcomes is poorly understood. We assessed the association of self-reported medication cost concerns and patient-reported outcomes (PROs) in a multiethnic SLE cohort | ||
| 520 | |a METHODS: The California Lupus Epidemiology Study is a cohort of individuals with physician-confirmed SLE. Medication cost concerns were defined as having difficulties affording SLE medications, skipping doses, delaying refills, requesting lower-cost alternatives, purchasing medications outside the United States, or applying for patient assistance programs. Linear regression and mixed effects models assessed the cross-sectional and longitudinal association of medication cost concerns and PROs, respectively, adjusting for age, sex, race and ethnicity, income, principal insurance, immunomodulatory medications, and organ damage | ||
| 520 | |a RESULTS: Of 334 participants, medication cost concerns were reported by 91 (27%). Medication cost concerns were associated with worse Systemic Lupus Activity Questionnaire (SLAQ; beta coefficient [β] 5.9, 95% CI 4.3-7.6; P < 0.001), 8-item Patient Health Questionnaire depression scale (PHQ-8; β 2.7, 95% CI 1.4-4.0; P < 0.001), and Patient-Reported Outcomes Measurement Information System (PROMIS; β for physical function -4.6, 95% CI -6.7 to -2.4; P < 0.001) scores after adjusting for covariates. Medication cost concerns were not associated with significant changes in PROs over 2-year follow-up | ||
| 520 | |a CONCLUSION: More than a quarter of participants reported at least 1 medication cost concern, which was associated with worse PROs. Our results reveal a potentially modifiable risk factor for poor outcomes rooted in the unaffordability of SLE care | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a drug costs | |
| 650 | 4 | |a healthcare disparities | |
| 650 | 4 | |a patient-reported outcome measures | |
| 650 | 4 | |a systemic lupus erythematosus | |
| 700 | 1 | |a DeQuattro, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a Shiboski, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Katz, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Greenlund, Kurt J |e verfasserin |4 aut | |
| 700 | 1 | |a Barbour, Kamil E |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Lanata, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Criswell, Lindsey A |e verfasserin |4 aut | |
| 700 | 1 | |a Dall'Era, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdany, Jinoos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of rheumatology |d 1983 |g 50(2023), 10 vom: 16. Okt., Seite 1302-1309 |w (DE-627)NLM000019593 |x 1499-2752 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:10 |g day:16 |g month:10 |g pages:1302-1309 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3899/jrheum.2023-0060 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 10 |b 16 |c 10 |h 1302-1309 | ||